Ca2+ as a mediator of ischemic preconditioning

Area of Science:

• Cardiology
• Molecular Biology
• Biochemistry

Background:

• Ischemic heart disease remains a leading cause of mortality.
• Cardioprotective strategies like ischemic preconditioning (IPC) offer therapeutic potential.
• The precise molecular mechanisms underlying IPC-induced cardioprotection require further elucidation.

Purpose of the Study:

• To investigate the role of intracellular calcium ([Ca2+]i) elevation in activating protein kinase C (PKC) during IPC.
• To determine if PKC activation is essential for the cardioprotective effects of IPC and high-Ca2+ preconditioning (HCPC).
• To identify specific PKC isoforms involved in IPC-mediated cardioprotection.

Main Methods:

• Langendorff-perfused rat hearts subjected to global ischemia/reperfusion (I/R).
• IPC and HCPC protocols implemented prior to I/R.
• Assessment of cardiac function, lactate dehydrogenase release, and ATP content.
• Pharmacological inhibition of PKC and calcium channels (verapamil, chelerythrine).
• Immunohistochemical analysis of PKC isoform translocation.

Main Results:

• Both IPC and HCPC significantly improved functional recovery and reduced injury markers post-I/R.
• Preconditioned hearts exhibited higher ATP levels and better structural preservation.
• PKC activation and translocation from cytoplasm to sarcolemma were observed in preconditioned hearts.
• Verapamil and chelerythrine abolished IPC/HCPC-induced cardioprotection and PKC translocation.
• PKC alpha and PKC delta isoforms were identified as key players translocating to the cell membrane.

Conclusions:

• Transient [Ca2+]i elevation during IPC is a critical trigger for PKC activation, mediating cardioprotection.
• Calcium influx via voltage-dependent channels contributes to the [Ca2+]i increase during IPC.
• Activation and translocation of PKC alpha and delta are integral to the cardioprotective effects of IPC and HCPC.